Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multidrug resistance.

J A Moscow1, K H Cowan

  • 1Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD 20892.

Journal of the National Cancer Institute
|March 2, 1988
PubMed
Summary

Cancer cells can resist chemotherapy through multidrug resistance (MDR). Understanding MDR mechanisms, like P-glycoprotein and drug-metabolizing enzymes, is key to improving cancer treatment effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation.

Oncogene·2014
Same author

Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response.

Oncogene·2010
Same author

Irradiation-induced G2/M checkpoint response requires ERK1/2 activation.

Oncogene·2007
Same author

Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same author

Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction.

The Journal of pharmacology and experimental therapeutics·2002
Same author

Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Malignant cells developing resistance to cytotoxic drugs is a significant challenge in cancer therapy.
  • Multidrug resistance (MDR) allows cancer cells to survive lethal doses of various antineoplastic agents.
  • P-glycoprotein overexpression is linked to MDR, potentially through drug efflux.

Purpose of the Study:

  • To explore the multifaceted mechanisms underlying multidrug resistance (MDR) in cancer.
  • To investigate the role of drug-metabolizing enzymes and topoisomerase activity in MDR.
  • To identify potential therapeutic targets for overcoming MDR in cancer chemotherapy.

Main Methods:

  • Analysis of biochemical similarities between MDR cancer cell lines and carcinogen-induced preneoplastic hepatic nodules.
  • Characterization of atypical MDR patterns associated with altered topoisomerase activity.
  • Review of evidence linking P-glycoprotein and drug-metabolizing enzymes to MDR.

Main Results:

  • Evidence suggests that altered regulation of phase I and phase II drug-metabolizing enzymes may contribute to MDR.
  • Atypical MDR has been identified and linked to changes in topoisomerase activity.
  • While P-glycoprotein is implicated, other resistance mechanisms are also involved in MDR.

Conclusions:

  • Multidrug resistance (MDR) involves complex mechanisms beyond P-glycoprotein.
  • Targeting drug-metabolizing enzymes and topoisomerase activity could offer new strategies to combat MDR.
  • Interfering with MDR mechanisms may enhance the efficacy of current cancer chemotherapy.

Related Experiment Videos